Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17549006 | 0.86 | TAAR1 (0.38) | TAAR1CYP2A6ALOX5 | |
| SCHEMBL407650 | 0.84 | POLB (0.39) | POLBL3MBTL1NPC1RAB9AALOX5 | |
| SCHEMBL15546625 | 0.82 | TAAR1 (0.39) | L3MBTL1PRMT6TAAR1CYP1A2CYP2A6 | |
| SCHEMBL20620458 | 0.81 | ALOX5 (0.35) | POLBL3MBTL1NPC1RAB9AALOX5 | |
| SCHEMBL19395990 | 0.78 | TAAR1 (0.41) | POLBL3MBTL1TAAR1CYP2A6 | |
| SCHEMBL459430 | 0.76 | CHRM2 (0.36) | POLBL3MBTL1NPC1RAB9AALOX5 | |
| SCHEMBL19396000 | 0.76 | TAAR1 (0.39) | POLBNPC1RAB9APRMT6TAAR1 | |
| SCHEMBL19248476 | 0.76 | TAAR1 (0.44) | NPC1RAB9APRMT6TAAR1CYP1A2 | |
| SCHEMBL17537872 | 0.75 | CYP2A6 (0.45) | L3MBTL1PRMT6TAAR1CYP1A2CYP2A6 | |
| SCHEMBL13541829 | 0.74 | ALDH1A1 (0.42) | POLBL3MBTL1NPC1RAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275236-A1 | DIAMINE COMPOUNDS, DINITRO COMPOUNDS AND OTHER COMPOUNDS, AND METHODS OF PRODUCING THEREOF AND USES RELATED THEREOF | MICROMIDAS, INC. (US) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275236-A1 | DIAMINE COMPOUNDS, DINITRO COMPOUNDS AND OTHER COMPOUNDS, AND METHODS OF PRODUCING THEREOF AND USES RELATED THEREOF | DDC, DDT, DAO | POLB 2749/4885L3MBTL1 4229/4885NPC1 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.